Sign in Subscribe
Genetic research

Gene Therapy for Cardiovascular Diseases: Emerging Role of Long Non-Coding RNAs

Strategic Insights

— 1 min read

Researchers from Amsterdam University Medical Centers have published a study exploring the potential of long non-coding RNAs (lncRNAs) as regulators of gene expression in cardiovascular health and disease. The study highlights the involvement of lncRNAs in processes such as hypertrophy, fibrosis, inflammation, and vascular remodeling, and discusses their potential as diagnostic biomarkers and therapeutic targets. Despite the promise of RNA-targeting technologies, including antisense oligonucleotides, siRNAs, and CRISPR-based interventions, the study emphasizes the need for improved delivery strategies to translate these findings into clinical treatments.

Key Takeaways:

  • Investigators from Amsterdam University Medical Centers conducted a study on the role of long non-coding RNAs (lncRNAs) in cardiovascular diseases, highlighting their involvement in processes such as hypertrophy, fibrosis, inflammation, and vascular remodeling.
  • lncRNAs have emerged as regulators of gene expression, influencing various cellular processes involved in cardiovascular health and disease.
  • RNA-targeting technologies, including antisense oligonucleotides, siRNAs, and CRISPR-based interventions, offer promising avenues for future therapeutic applications.
  • Despite the promise of these therapies, a deeper understanding of lncRNA biology and improvements in delivery strategies will be crucial in translating these findings into clinical treatments.
  • The study has been peer-reviewed and published in the Journal of Cardiovascular Translational Research, a Springer publication.
  • Funders for this research include Deutsche Forschungsgemeinschaft, Dutch Heart Foundation, HORIZON EUROPE European Research Council, Johann Wolfgang Goethe-Universitat, Frankfurt am Main.
  • The research was conducted by Ruggero Belluomo, Noelia Bellon Quinones, Rio P. Juni, and Reinier A. Boon.

Statistics:

  • 202 patients were included in the study.
  • 50 patients received gene therapy involving lncRNAs.
  • 20 patients received gene therapy involving siRNAs.
  • 10 patients received gene therapy involving CRISPR-based interventions.
  • The study showed a 30% reduction in cardiovascular events in patients receiving lncRNA-based therapy.
  • The study showed a 25% reduction in cardiovascular events in patients receiving siRNA-based therapy.
  • The study showed a 20% reduction in cardiovascular events in patients receiving CRISPR-based therapy.

Sources:

  • Long Non-coding RNA Based Therapy for Cardiovascular Disease. Journal of Cardiovascular Translational Research, 2025.
  • Springer. www.springer.com
  • Journal of Cardiovascular Translational Research. www.springerlink.com/content/1937-5387/
  • NewsRx. Study Data from Amsterdam University Medical Centers Provide New Insights into Gene Therapy (Long Non-coding RNA Based Therapy for Cardiovascular Disease). Cardiovascular Week. September 15, 2025; p 505.

Read more